NCT05607004 - (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 14, 2023

Primary Completion Date

November 30, 2026

Study Completion Date

April 30, 2027

Conditions

Breast NeoplasmsInvasive Breast CancerEstrogen-receptor-positive Breast CancerHER2-negative Breast Cancer

Interventions

DRUG

(Z)-endoxifen

(Z)-endoxifen capsules. Doses of (Z)-endoxifen to be evaluated include 20 mg (two x 10 mg capsules), 40 mg (one 40 mg capsule) and 80 mg (two x 40 mg capsules).

DRUG

goserelin

goserelin 3.6 mg subcutaneous implant

Trial Locations (14)

23114

RECRUITING

Bon Secours Cancer Institute, Midlothian

32224

RECRUITING

Mayo Clinic Florida, Jacksonville

37204

RECRUITING

Vanderbilt Ingram Cancer Center, Nashville

41017

RECRUITING

St. Elizabeth Healthcare, Edgewood

48202

RECRUITING

Henry Ford Cancer Institute, Detroit

55905

RECRUITING

Mayo Clinic Rochester, Rochester

57105

RECRUITING

Avera Cancer Institute, Sioux Falls

60611

RECRUITING

Northwestern University, Chicago

63110

RECRUITING

Washington University School of Medicine, St Louis

77054

RECRUITING

Baylor University, Houston

77598

WITHDRAWN

Tranquility Research, Webster

85054

RECRUITING

Mayo Clinic Arizona, Phoenix

85719

RECRUITING

University of Arizona, Tucson

90027

RECRUITING

California Research Institute, Los Angeles